Arcus Biosciences (RCUS) Total Non-Current Liabilities (2017 - 2026)

Arcus Biosciences' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $354.0 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 29.62% year-over-year to $354.0 million; the TTM figure through Mar 2026 stood at $354.0 million (down 29.62% YoY), while the FY2025 annual figure was $373.0 million, down 26.57% from the prior year.
• Total Non-Current Liabilities was $354.0 million for Q1 2026 at Arcus Biosciences, down from $373.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $733.0 million in Q1 2022 to a low of $354.0 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $508.0 million across 5 years, with a median of $503.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 181.77% in 2022, then plunged 35.56% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $503.0 million in 2022, then slipped by 2.39% to $491.0 million in 2023, then grew by 3.46% to $508.0 million in 2024, then slipped by 26.57% to $373.0 million in 2025, then declined by 5.09% to $354.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $354.0 million (Q1 2026), $373.0 million (Q4 2025), and $386.0 million (Q3 2025), per Business Quant data.